These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3245935)

  • 1. Advanced Lewis lung carcinoma cured by tiazofurin as a system to study delayed hemopoietic effects of cancer.
    Balducci L; Hardy CL
    Cancer Invest; 1988; 6(6):681-6. PubMed ID: 3245935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early hematopoietic events during tumor growth in mice.
    Hardy CL; Balducci L
    J Natl Cancer Inst; 1986 Mar; 76(3):535-40. PubMed ID: 3485212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High proliferation of granulocyte-macrophage progenitors in tumor-bearing mice.
    Balducci L; Hardy C
    Cancer Res; 1983 Oct; 43(10):4643-7. PubMed ID: 6883322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High proliferation of early hemopoietic progenitors in tumor-bearing mice.
    Balducci L; Hardy CL
    Pathobiology; 1992; 60(2):68-71. PubMed ID: 1571093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of tiazofurin (NSC 286193) in treating disseminated tumor cells and micrometastases in mice.
    Lapis K; Pápay J; Paku S
    Oncology; 1990; 47(4):359-64. PubMed ID: 2367062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
    Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
    Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematological and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia.
    Tricot GJ; Jayaram HN; Nichols CR; Pennington K; Lapis E; Weber G; Hoffman R
    Cancer Res; 1987 Sep; 47(18):4988-91. PubMed ID: 3476200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin.
    Finlay GJ; Ching LM; Wilson WR; Baguley BC
    J Natl Cancer Inst; 1987 Aug; 79(2):291-6. PubMed ID: 3474463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ribavirin on the development of the Friend leukemia.
    Opitz U; Seidel HJ; Streissle G
    J Cancer Res Clin Oncol; 1980; 98(1):41-50. PubMed ID: 7451552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of high-dose methotrexate and leucovorin on murine hemopoietic stem cells.
    Pannacciulli I; Massa G; Bogliolo G; Ghio R; Sobrero A
    Cancer Res; 1982 Feb; 42(2):530-4. PubMed ID: 6976827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
    J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological alterations in blood and bone marrow of ribavirin-treated monkeys.
    Cosgriff TM; Hodgson LA; Canonico PG; White JD; Kastello MD; Donovan JC; Ross PE
    Acta Haematol; 1984; 72(3):195-200. PubMed ID: 6438984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2.
    Young MR; Young ME; Kim K
    Cancer Res; 1988 Dec; 48(23):6826-31. PubMed ID: 2972359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoprotective features of selenazofurin in hematopoietic cells.
    Pogrebniak A; Hasmann M; Schemainda I; Pelka-Fleischer R; Nuessler V
    Int J Clin Pharmacol Ther; 2002 Aug; 40(8):368-75. PubMed ID: 12467305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma.
    Holoye PY; Carr DT; Dhingra HM; Glisson BS; Lee JS; Murphy WK; Umsawasdi T; Jeffries D
    Invest New Drugs; 1988 Sep; 6(3):217-8. PubMed ID: 2847992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) against untreated human ovarian cancers in the murine xenograft assay.
    Micha JP; Kucera PR; Preve CU; Rettenmaier MA; Stratton JA; DiSaia PJ
    Gynecol Oncol; 1985 Jul; 21(3):351-5. PubMed ID: 4007612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
    Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
    Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms mediating the inhibitory effect of all-trans retinoic acid on primitive hematopoietic stem cells in human long-term bone marrow culture.
    Sammons J; Ahmed N; Khokher MA; Hassan HT
    Stem Cells; 2000; 18(3):214-9. PubMed ID: 10840075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual injury to the hemopoietic microenvironment following sequential radiation and busulfan.
    Wathen LM; DeGowin RL; Gibson DP; Knapp SA
    Int J Radiat Oncol Biol Phys; 1982 Aug; 8(8):1315-22. PubMed ID: 7141910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential induction of hematopoiesis and immune suppressor cells in the bone marrow versus in the spleen by Lewis lung carcinoma variants.
    Young MR; Aquino S; Young ME
    J Leukoc Biol; 1989 Mar; 45(3):262-73. PubMed ID: 2522492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.